| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/24/2009 | US20090239236 Gene detection assay for improving the likelihood of an effective response to an egfr antagonist cancer therapy |
| 09/24/2009 | US20090238885 Protein encapsulated particles |
| 09/24/2009 | US20090238818 Induction of Antigen Specific Immunnologic Tolerance |
| 09/24/2009 | US20090238803 Human cord blood derived unrestricted somatic stem cells (ussc) |
| 09/24/2009 | CA2728756A1 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| 09/23/2009 | EP2103629A1 Gamma -1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
| 09/23/2009 | EP2103628A1 Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| 09/23/2009 | EP2103624A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 09/23/2009 | EP2103620A1 Fused heterocyclic compound |
| 09/23/2009 | EP2103619A1 Imidazothiazole derivatives |
| 09/23/2009 | EP2103607A1 1-phenyl 1-thio-d-glucitol derivative |
| 09/23/2009 | EP2103306A2 Use of a 5'-nucleotide for preventing/improving functional digestive disorder |
| 09/23/2009 | EP2102235A1 Treatment of cachexia |
| 09/23/2009 | EP2101752A1 Use of prodrugs of gaba analogs for treating diseases |
| 09/23/2009 | EP2101748A2 Uses of incensole, incensole acetate and derivatives thereof |
| 09/23/2009 | EP1621207B1 Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors |
| 09/23/2009 | EP1567497B1 Pyridines for treating injured mammalian nerve tissue |
| 09/23/2009 | EP1508561B1 2-(a-HYDROXYPENTYL) BENZOATE AND ITS PREPARATION AND USE |
| 09/23/2009 | EP1467989B1 Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection |
| 09/23/2009 | EP1461038B9 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 09/23/2009 | EP1416966B1 Methods for treating joint inflammation, pain, and loss of mobility |
| 09/23/2009 | EP1377288B1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and use |
| 09/23/2009 | EP1283682B1 Tryptophan source from plants and uses therefor |
| 09/23/2009 | EP1003781B1 Interleukin-18 binding proteins, their preparation and use |
| 09/23/2009 | EP0946508B1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
| 09/23/2009 | CN101538254A Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme |
| 09/23/2009 | CN101538245A One-class pyridazinone compounds and preparation method and application thereof |
| 09/23/2009 | CN101538244A 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
| 09/23/2009 | CN101537182A Combination comprising an HMG CoA reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 09/23/2009 | CN101537181A Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure |
| 09/23/2009 | CN101537154A Manufacturing method of medicament for treating ten kinds of diseases |
| 09/23/2009 | CN100543143C Process for enhanced production of pantothenate |
| 09/23/2009 | CN100543022C 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same |
| 09/23/2009 | CN100542612C Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 09/23/2009 | CN100542606C Vaccine composition comprising tumour antigen and adjuvant composition |
| 09/23/2009 | CN100542530C 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 09/23/2009 | CN100542527C Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same |
| 09/22/2009 | US7592477 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) |
| 09/22/2009 | US7592455 potent and selective inhibitors of p38 kinase, especially p38 alpha , p38 beta and p38 beta 2; immune or inflammatory disorders; Ethyl 3-(benzylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate |
| 09/22/2009 | US7592450 used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability |
| 09/22/2009 | US7592368 HIV aspartyl protease inhibitors; solubility, bioavailability; viral and HIV infections |
| 09/22/2009 | US7592356 and geranylgeranyltransferase inhibitor; 3-chloromethyl-4-cyanobenzyl-5 methyl triazole; antitumor agents; prevent membrane attachment of protein p21ras and block aberrant growth of ras-transformed tumors; capable to inhibit prenylation of Ras proteins, both at enzymatic and cellular level |
| 09/22/2009 | US7592339 Substituted oxazolidinones and their use in the field of blood coagulation |
| 09/22/2009 | US7592323 Testosterone-repressed prostate message-2 (TRPM-2); delaying progression of prostatic tumor cells to an androgen-independent state |
| 09/22/2009 | US7592316 Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 09/22/2009 | US7592310 Induction of antibiotic proteins and peptides by LAIT/sCD14-protein |
| 09/22/2009 | US7592012 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 09/22/2009 | US7592004 Lyophilizing an aqueous formulation comprising a high concentration, 50 mg/ml or more of an immunoglobulin IgG antibody, in particular, daclizumab, in 5-25 mM histidine buffer, having pH 5.5-6.5, 0.005%-0.03% polysorbate, and sucrose |
| 09/22/2009 | CA2487450C (2s)-2-ethylphenylpropanoic acid derivatives |
| 09/22/2009 | CA2449917C Amino acid mixture-containing agent capable of raising body temperature for food or drink use and medical use |
| 09/22/2009 | CA2426349C Over-coated chewing gum formulations including tableted center |
| 09/22/2009 | CA2419588C Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 09/22/2009 | CA2402121C Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/22/2009 | CA2399451C Tyrosine derivatives with anti-leukotriene activity |
| 09/22/2009 | CA2398274C Adenosine receptor modulators |
| 09/22/2009 | CA2397554C Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 09/22/2009 | CA2360894C (1-phenacyl-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same |
| 09/22/2009 | CA2194476C Anti-adhesion agent |
| 09/22/2009 | CA2152351C Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor |
| 09/17/2009 | WO2009114040A2 Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| 09/17/2009 | WO2009113665A1 Method of producing drug for swine atrophic rhinitis |
| 09/17/2009 | WO2009113664A1 Recombinant dermonecrotic toxoid-containing drug for swine atrophic rhinitis |
| 09/17/2009 | WO2009113600A1 Pyridylaminoacetic acid compound |
| 09/17/2009 | WO2009113579A1 Double-stranded nucleic acid molecule suitable for prevention or treatment of cancer, cancer cell proliferation inhibitor, and pharmaceutical preparation |
| 09/17/2009 | WO2009113560A1 Fused heterocyclic compound |
| 09/17/2009 | WO2009113480A1 Therapeutic agent for cerebral infarction |
| 09/17/2009 | WO2009113436A1 Method for enhancing the anti-cancer activity of radioactive ray by using fgf33 gene inhibitor in combination with irradiation with the radioactive ray, and method for reducing adverse side effects of radioactive ray |
| 09/17/2009 | WO2009113423A1 Bicyclic pyrrole compound |
| 09/17/2009 | WO2009113420A1 Improvement of dissolvability of preparation containing olmesartan medoxomil |
| 09/17/2009 | WO2009112653A2 Cosmetic and/or dermatological composition |
| 09/17/2009 | US20090234003 Carbamate compounds for use in preventing or treating anxiety disorders |
| 09/17/2009 | US20090234000 Triptolide Analogs for the Treatment of Autoimmune and Inflammatory Disorders |
| 09/17/2009 | US20090233997 Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same |
| 09/17/2009 | US20090233858 Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation |
| 09/17/2009 | US20090233849 Recombinant Alpha-Fetoprotein, Method and Means for Preparation Thereof, Compositions on the Base Thereof and Use Thereof |
| 09/17/2009 | US20090233813 Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors |
| 09/17/2009 | US20090233314 Functional domain and associated molecule of dock2 essentially required in lymphocyte migration |
| 09/17/2009 | US20090232864 Method for applying a bioactive, tissue-compatible layer onto shaped articles and the use of such shaped articles |
| 09/17/2009 | US20090232857 Method and process for the production of multi-coated recognitive and releasing systems |
| 09/17/2009 | US20090232816 Il-1 eta dna and polypeptides |
| 09/17/2009 | US20090232809 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/17/2009 | US20090232737 Purification of proteins |
| 09/17/2009 | CA2718393A1 Pyridylaminoacetic acid compound |
| 09/17/2009 | CA2718252A1 Bicyclic pyrrole compound |
| 09/16/2009 | EP2100901A1 Modified Insulin and conjugates thereof |
| 09/16/2009 | EP2100893A1 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| 09/16/2009 | EP2100891A1 Inhibitors of tyrosine kinases |
| 09/16/2009 | EP2100876A2 New compounds for the inhibition of rotamases and use thereof |
| 09/16/2009 | EP2100617A1 Methods of modulating CD200 receptors |
| 09/16/2009 | EP2100615A1 Cancer therapy |
| 09/16/2009 | EP2099469A2 Radiation protection and treatment for exposure to gamma-radiation |
| 09/16/2009 | EP2099453A2 Combination therapy of substituted oxazolidinones |
| 09/16/2009 | EP1661909B1 Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food |
| 09/16/2009 | EP1564210B1 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
| 09/16/2009 | EP1523471B1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 09/16/2009 | EP1487807B1 Cyano-pyrrolidines as DPP-IV inhibitors |
| 09/16/2009 | EP1478656B1 Oligonucleotide compositions with enhanced efficiency |
| 09/16/2009 | EP1478364B1 Selective antibacterial agents |
| 09/16/2009 | EP1414948B1 Inhibition of apoptosis process and improvement of cell performance |
| 09/16/2009 | EP1414825B9 Thienopyrimidinediones and their use in the modulation of autoimmune disease |